RECURRENT NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or not responded to standard therapy. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest dose, un…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 11:39 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogni…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated May 26, 2026 11:39 UTC
-
Engineered immune cells take on HIV-Linked cancers
Disease control Recruiting nowThis phase 1 trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer c…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated May 26, 2026 11:35 UTC
-
Immune boosting NK cells show promise in blood cancer trial
Disease control Recruiting nowThis study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to prior treatments. The therapy…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC